Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Canada pools resources in wide-ranging strategy:

This article was originally published in Clinica

Executive Summary

Canada is to strengthen its resources to fight cancer with the implementation of a Canadian Strategy for Cancer Control (CSCC). The programme, which was launched in November 2006 and allocated Can$260m (US$241m) over five years, is currently in the planning process. It aims to effectively tap the country's knowledge bank to improve prevention, diagnosis and treatment of cancer. The CSCC is constituted of "key players" in several fields, including primary prevention, screening/early detection, surveillance, diagnostics and research. In 2007 it is predicted that Canada will see around 159,000 new cases of cancer and 72,700 deaths from cancer. Overall, lung cancer and colorectal cancer are, respectively, the leading and the second leading causes of death from cancer in Canada.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT048729

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel